MA46109A - Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes - Google Patents

Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes

Info

Publication number
MA46109A
MA46109A MA046109A MA46109A MA46109A MA 46109 A MA46109 A MA 46109A MA 046109 A MA046109 A MA 046109A MA 46109 A MA46109 A MA 46109A MA 46109 A MA46109 A MA 46109A
Authority
MA
Morocco
Prior art keywords
kits
methods
low viscosity
antibody formulations
inhibitor antibody
Prior art date
Application number
MA046109A
Other languages
English (en)
Inventor
Gregory A Demopulos
Kenneth M Ferguson
William Joseph Lambert
John Steven Whitaker
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MA46109A publication Critical patent/MA46109A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA046109A 2016-08-31 2017-08-30 Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes MA46109A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662382156P 2016-08-31 2016-08-31

Publications (1)

Publication Number Publication Date
MA46109A true MA46109A (fr) 2019-07-10

Family

ID=61301617

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046109A MA46109A (fr) 2016-08-31 2017-08-30 Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes

Country Status (40)

Country Link
US (2) US11628217B2 (fr)
EP (2) EP4438060A3 (fr)
JP (2) JP6864747B2 (fr)
KR (2) KR20190043161A (fr)
CN (3) CN116327695A (fr)
AR (1) AR109494A1 (fr)
AU (2) AU2017321605B2 (fr)
CA (1) CA3035252C (fr)
CL (1) CL2019000508A1 (fr)
CO (1) CO2019002239A2 (fr)
CR (1) CR20190150A (fr)
CU (1) CU20190015A7 (fr)
DK (1) DK3506886T3 (fr)
EA (1) EA201990598A1 (fr)
EC (1) ECSP19021312A (fr)
ES (1) ES2986902T3 (fr)
FI (1) FI3506886T3 (fr)
GE (1) GEP20217252B (fr)
HR (1) HRP20241131T1 (fr)
HU (1) HUE068084T2 (fr)
IL (1) IL265071B2 (fr)
JO (1) JOP20170170B1 (fr)
LT (1) LT3506886T (fr)
MA (1) MA46109A (fr)
MX (2) MX2019002338A (fr)
MY (1) MY189411A (fr)
PE (1) PE20190469A1 (fr)
PH (1) PH12019500365A1 (fr)
PL (1) PL3506886T3 (fr)
PT (1) PT3506886T (fr)
PY (1) PY1763675A (fr)
RS (1) RS65845B1 (fr)
SG (2) SG11201901444PA (fr)
SI (1) SI3506886T1 (fr)
SM (1) SMT202400333T1 (fr)
TW (2) TWI719245B (fr)
UA (1) UA122733C2 (fr)
UY (1) UY37391A (fr)
WO (1) WO2018045054A1 (fr)
ZA (1) ZA201901891B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102528260B1 (ko) * 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EP3525798A4 (fr) * 2016-10-13 2020-07-08 University Of Leicester Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a
KR20200037863A (ko) * 2017-08-25 2020-04-09 오메로스 코포레이션 고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
WO2020016417A1 (fr) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Formulation d'anticorps liquide
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
EP4069676A1 (fr) 2019-12-04 2022-10-12 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
EP4069678A1 (fr) 2019-12-04 2022-10-12 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
JP2023537316A (ja) 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
JP2023547621A (ja) * 2020-10-22 2023-11-13 アラコス インコーポレイテッド 抗ｓｉｇｌｅｃ－８抗体製剤
CA3221859A1 (fr) * 2021-06-08 2022-12-15 Xiaowu Liu Anticorps anti-masp-2 et son utilisation
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2023173036A2 (fr) * 2022-03-10 2023-09-14 Omeros Corporation Inhibiteurs de masp-2 et masp-3, et compositions et méthodes associées pour le traitement de la drépanocytose
EP4626891A1 (fr) 2022-11-30 2025-10-08 Omeros Corporation Pyrimidines fusionnées en tant qu'inhibiteurs de masp-2
EP4643878A2 (fr) * 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Préparation pharmaceutique comprenant un anticorps thérapeutique et son utilisation
WO2024226573A2 (fr) * 2023-04-25 2024-10-31 Nuvance Health Méthodes de traitement du cancer dirigé par masp-2
US12216123B2 (en) 2023-04-25 2025-02-04 Nuvance Health Extracellular vesicle derived MASP-2 directed cancer treatment methods
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
CN121490076A (zh) * 2026-01-13 2026-02-10 上海麦济医药有限公司 一种稳定的抗人masp2单克隆抗体制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
BR112013025917A2 (pt) * 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
WO2014141149A1 (fr) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations présentant une viscosité réduite
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
CA2959571A1 (fr) * 2014-09-03 2016-03-10 Medimmune Limited Formulation stable d'anticorps anti-il-4r-alpha
WO2016109822A1 (fr) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
AU2016354117B2 (en) 2015-11-09 2019-11-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20170253667A1 (en) 2016-01-05 2017-09-07 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
KR102528260B1 (ko) 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
MX2018011648A (es) 2016-03-31 2019-01-30 Omeros Corp Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法

Also Published As

Publication number Publication date
EP4438060A3 (fr) 2024-12-25
IL265071B2 (en) 2023-12-01
CN116327695A (zh) 2023-06-27
US20230226178A1 (en) 2023-07-20
US20180153988A1 (en) 2018-06-07
RS65845B1 (sr) 2024-09-30
IL265071B1 (en) 2023-08-01
EA201990598A1 (ru) 2019-07-31
WO2018045054A1 (fr) 2018-03-08
CR20190150A (es) 2019-05-14
AU2017321605A1 (en) 2019-02-07
US11628217B2 (en) 2023-04-18
IL265071A (fr) 2019-04-30
ES2986902T3 (es) 2024-11-13
TWI730310B (zh) 2021-06-11
CN109890367B (zh) 2022-08-30
DK3506886T3 (da) 2024-08-19
EP3506886A4 (fr) 2019-10-09
HRP20241131T1 (hr) 2024-11-22
TW201944983A (zh) 2019-12-01
ZA201901891B (en) 2019-12-18
AU2020277135A1 (en) 2020-12-24
MX2023014120A (es) 2023-12-12
EP3506886B1 (fr) 2024-05-22
EP4438060A2 (fr) 2024-10-02
AU2020277135B2 (en) 2023-11-02
ECSP19021312A (es) 2019-04-30
CO2019002239A2 (es) 2019-03-18
TW201811365A (zh) 2018-04-01
KR20190043161A (ko) 2019-04-25
CN109890367A (zh) 2019-06-14
CU20190015A7 (es) 2019-11-04
MY189411A (en) 2022-02-10
SG11201901444PA (en) 2019-03-28
SI3506886T1 (sl) 2024-09-30
CA3035252C (fr) 2021-08-10
GEP20217252B (en) 2021-05-13
JP7197623B2 (ja) 2022-12-27
AR109494A1 (es) 2018-12-12
JP2019531341A (ja) 2019-10-31
LT3506886T (lt) 2024-09-10
JP2021105033A (ja) 2021-07-26
JOP20170170A1 (ar) 2019-01-30
KR102444154B1 (ko) 2022-09-16
CA3035252A1 (fr) 2018-03-08
SMT202400333T1 (it) 2024-09-16
MX2019002338A (es) 2019-08-16
KR20210135618A (ko) 2021-11-15
PY1763675A (es) 2019-01-01
JOP20170170B1 (ar) 2022-09-15
NZ751988A (en) 2021-09-24
PH12019500365A1 (en) 2019-11-04
JP6864747B2 (ja) 2021-04-28
PE20190469A1 (es) 2019-04-04
SG10202100697PA (en) 2021-02-25
UY37391A (es) 2018-02-28
EP3506886A1 (fr) 2019-07-10
PL3506886T3 (pl) 2024-12-16
TWI719245B (zh) 2021-02-21
CL2019000508A1 (es) 2019-06-28
UA122733C2 (uk) 2020-12-28
CN116327917A (zh) 2023-06-27
BR112019003479A2 (pt) 2019-05-21
AU2017321605B2 (en) 2020-10-08
FI3506886T3 (fi) 2024-08-20
HUE068084T2 (hu) 2024-12-28
PT3506886T (pt) 2024-08-21

Similar Documents

Publication Publication Date Title
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
EP3724341A4 (fr) Procédés et compositions pour la tolérance à l'herbicide ppo
EP3735685A4 (fr) Panneau d'affichage
EP3843729A4 (fr) Nouvelles compositions et méthodes
MA46923A (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
EP3750149C0 (fr) Panneau d'affichage
EP3641768A4 (fr) Récepteurs d'antigènes chimériques (car), compositions et méthodes associées
EP3607587A4 (fr) Panneau d'affichage
WO2018075692A3 (fr) Constructions d'anticorps
EP3600325A4 (fr) Nouvelles compositions et méthodes
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3445407A4 (fr) Compositions et méthodes d'immunothérapie cellulaire
MA46525A (fr) Anticorps anti-lag-3 et compositions
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
BR112019012343A2 (pt) anticorpos il-11ra
EP3377657A4 (fr) Compositions de marquage transformable, méthodes et procédés les comprenant
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
EP3798719A4 (fr) Panneau d'affichage
EP3436083A4 (fr) Nouvelles compositions et méthodes